ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

309

HTML

2264

Figures (1-5)

167

Tables (1-2)

129

Sum=2869

Nov 7, 2008 (publication date) through Apr 22, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 7, 2008; 14(41): 6401-6407
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6401

Table 1 The sequences of primers and probes

Primers or probes	Sequences (5'-3')	Length ofproduct (bp)
actin-U	AGAAGATGACCCAGATCATGTT	290
actin-L	CTTAATGTCACGCACGATTTCC
ERCC1-U	TACCACAACCTGCACCCAGACTAC	321
ERCC1-L	CTGACTGTCCGTTTTGTTGACTGA
ERCC1-118-U	GGTCATCCCTATTGATGGCTTCTG	154
ERCC1-118-L	AGCTCACCTGAGGAACAGGGCACAG
ERCC1-118-P	p-TTGCGCACGAACTTCAGTACGGGAT
	GGGACACTAATCGGAGGATTA-FAM
ERCC1-118-T	CTACGGAG GATTATGAGGAGCTGCGT	92
	CGCCAAATTCCCAGGGCACA
ERCC1-118-C	CTACGAAATCAGGAGGATTATGAGGA	97
	GACGTCGCCAAATTCCCAGGG CACG

Citation: Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008; 14(41): 6401-6407
URL: https://www.wjgnet.com/1007-9327/full/v14/i41/6401.htm
DOI: https://dx.doi.org/10.3748/wjg.14.6401